Grosshansdorf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomSchleswig holsteinHenrik watzDennis riedlDave singhMaria bechGinny norrisPulmonary research instituteEpiendo pharmaceuticalsUniversity of manchesterWorld economic forumEndo pharmaceuticalsChronic obstructive pulmonary diseasePrincipal investigatorsProfessor dave singhRespiratory pharmacology

EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

REYKJAVIK, Iceland, April 10, 2024 EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).

United kingdomSchleswig holsteinGinny norrisMaria bechDave singhHenrik watzEpiendo pharmaceuticalsUniversity of manchesterWorld economic forumPulmonary research instituteChronic obstructive pulmonary diseasePrincipal investigatorsProfessor dave singhRespiratory pharmacologyMedical directorMedicines evaluation unit

Mirati Therapeutics - European Commission Approves KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation

Switzerland - Mirati Therapeutics, Inc. , a commercial stage biotechnology company, today announced that the European Commission granted conditional marketing authorization for KRAZATI as a.

Schleswig holsteinMartin reckCharles baumEuropean commissionExchange commissionEuropean unionUnion registerCommittee for medicinal products human useEuropean medicines agencyMirati therapeutics incLung clinicMedicinal productsHuman useProduct characteristicsMedicines agencyNews publishing

Mirati Therapeutics (MRTX) Announces European Commission Approves KRAZATI as Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation

Mirati Therapeutics (MRTX) Announces European Commission Approves KRAZATI as Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Schleswig holsteinMartin reckCharles baumCommittee for medicinal products human useEuropean commissionMirati therapeutics incEuropean unionMirati therapeuticsLung clinicMedicinal productsHuman use

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that the European Commission granted.

Schleswig holsteinCharles baumMartin reckUnion registerCommittee for medicinal products human useEuropean unionPrnewswire mirati therapeutics incExchange commissionEuropean medicines agencyMirati therapeutics incEuropean commissionLung clinic grosshansdorfMedicinal productsHuman useMirati therapeuticsProduct characteristics